Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins

Kidney International

Volumn 63, Issue 5, 2003, Pages 1764-1775

  D'Hooge, Rudi ^a   Van De Vijver, Gerda ^b   Van Bogaert, Pierre Paul ^b   Marescau, Bart ^b   Vanholder, Raymond ^b   De Deyn, Peter P ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NONE

Author keywords

Calcium channels; Guanidines; NMDA receptors; Polyamines; Uremia

Indexed keywords

CALCIUM CHANNEL; GUANIDINE DERIVATIVE; GUANIDINOSUCCINIC ACID; HOMOCYSTEINE; INDOLE DERIVATIVE; INOSITOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; OROTIC ACID; PHENOL DERIVATIVE; POLYAMINE; POTASSIUM CHANNEL; PURINE DERIVATIVE; SPERMINE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHANNEL GATING; CLONIC SEIZURE; DRUG POTENTIATION; EMBRYO; KIDNEY FAILURE; MALE; MEMBRANE CONDUCTANCE; MOLECULAR INTERACTION; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SPINAL CORD; UREMIA;

EID: 0037407239     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00912.x     Document Type: Article

References (67)

1. NISSENSON AR, MARSH JT, BROWN WS, WOLCOTT DL: Central nervous system function in dialysis patients: a practical approach. Semin Dial 4:115-123, 1991
2. DE DEYN PP, SAXENA VK, ABTS H, et al: Clinical and pathophysiological aspects of neurological complications in renal failure. Acta Neurol Belg 92:191-206, 1992
3. FRASER CL: Neurologic manifestations of the uremic state, in Metabolic Brain Dysfunction in Systemic Disorders, edited by ARIEFF AI, GRIGGS RC, Boston, Little Brown & Co., 1992
4. MOE SM, SPRAGUE SM: Uremic encephalopathy. Clin Nephrol 42:251-256, 1994
5. BAKER LRI, BROWN AL, BYRNE J, et al: Head scan appearances and cognitive function in renal failure. Clin Nephrol 32:242-248, 1989
6. NISSENSON AR, LEVIN ML, KLAWANS HL, NAUSIEDA PL: Neurological sequelae of end stage renal disease ESRD. J Chronic Dis 30:705-733, 1977
7. ROTUNDO A, NEVINS TE, LIPTON M, et al: Progressive encephalopathy in children with chronic renal insufficiency in infancy. Kidney Int 21:486-491, 1982
8. STEINBERG A, EFRAT R, POMERANZ A, DRUKKER A: Computerized tomography of the brain in children with chronic renal failure. Int J Pediatr Nephrol 6:121-126, 1986
9. POLINSKY MS, KAISER BA, STOVER JB, et al: Neurological development of children with severe chronic renal failure from infancy. Pediatr Nephrol 1:157-165, 1987
10. FENNELL RS, FENNELL EB, CARTER RL, et al: Association between renal function and cognition in childhood chronic renal failure. Pediatr Nephrol 4:16-20, 1990
11. VANHOLDER R, ARGILES A, BAURMEISTER U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
12. MASSRY SG, FADDA GZ: Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis 71:81-86, 1993
13. VANHOLDER R, DE SMET R: Pathophysiologic effect of uremic retention solutes. J Am Soc Nephrol 10:1815-1823, 1999
14. DHONDT A, VANHOLDER R, VAN BIESEN W, LAMEIRE N: The removal of uremic toxins. Kidney Int 58 (Suppl 76):S47-S59, 2000
15. MARTY A, NEHER E: Tight-seal whole-cell recording, in Single-Channel Recording, edited bv SAKMANN B, NEHER E, New York, Plenum Press, 1995
16. THOMPSON GW, HORACKOVA M, ARMOUR JA: Ion channel modifying agents influence the electrical activity generated by canine intrinsic cardiac neurons in situ. Can J Physiol Pharmacol 78:293-300, 2000
17. RANSOM BR, BULLOCK PN, NELSON PG: Mouse spinal cord in cell culture III. Neuronal chemosensitivity and its relationship to synaptic activity. J Neurophysiol 40:1163-1177, 1977
18. HAMILL OP, MARTY A, NEHER E, et al: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85-100, 1981
19. D'HOOGE R, PEI YQ, MARESCAU B, DE DEYN PP: Convulsive action and toxicity of uremic guanidino compounds: Behavioral assessment and relation to brain concentration in adult mice. J Neurol Sci 112:96-105, 1992
20. WEIL CS: Tables for the convenient calculation of median-effective dose LD50 or ED50 and instructions in their use. Biometrics 8:249-263, 1952
21. LITCHFIELD JT, WILCOXON F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113, 1949
22. RINGOIR S, SCHOOTS A, VANHOLDER R: Uremic toxins. Kidney Int 33(Suppl 24):S4-S9, 1988
23. HÖRL WH: Uremic toxins: New aspects. J Nephrol 13 (Suppl 3):S83-S88, 2000
24. SAITO A, NIWA T, MAEDA K, et al: Tryptophan and indolic tryptophan metabolites in chronic renal failure. Am J Clin Nutr 33:1402-1406, 1980
25. QURESHI GA, BAIG SM: The role of tryptophan 5-hydroxy indole-3-acetic acid and their protein binding in uremic patients. Biochem Mol Biol Int 29:411-419, 1993
26. TAVARES-ALMEIDA I, GULYASSY PF, DEPNER TA, JARRARD EA: Aromatic amino acid metabolites as potential protein binding inhibitors in human uremic plasma. Biochem Pharmacol 34:2431-2438, 1985
27. DE SMET R, VOGELEERE P, VAN KAER J, et al: Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. J Chromatogr A 847:141-153, 1999
28. HIDA M, AIBA Y, SAWAMURA S, et al: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin a lactic acid bacteria preparation to uremic patients undergoing hemodialysis. Nephron 74:349-355, 1996
29. NIWA T: Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 39:108-111, 1993
30. DE SMET R, DAVID F, SANDRA P, et al: A sensitive HPCL method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 278:1-21, 1998
31. VANHOLDER R, DE SMET R, LESAFFER G: p-Cresol: A toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 14:2813-2815, 1999
32. NIWA T, ISE M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124:96-104, 1994
33. GRECO AV, MINGRONE G, FAVUZZI A, et al: Subclinical hepatic encephalopathy: Role of tryptophan binding to albumin and the competition with indole-3-acetic acid. J Investig Med 48:274-280, 2000
34. ENOMOTO A, TAKEDA M, TOJO A, et al: Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 13:1711-1720, 2002
35. + channels by phenol p-cresol and benzylalcohol. Mol Pharmacol 51:475-483, 1997
36. YEHUDA S, CARASSO RL, MOSTOFSKY DL: Essential fatty acid preparation SR-3 raises the seizure threshold in rats. Eur J Pharmacol 254:193-198, 1994
37. ANGEL A, RODGERS KJ: An analysis of the convulsant activity of substituted benzenes in the mouse. Toxicol Appl Pharmacol 21:214-229, 1972
38. BLABER LC, GALLAGHER JP: The facilitatory effects of catechol and phenol at the neuromuscular junction of the cat. Neuropharmacology 10:153-159, 1971
39. + channels. Toxicol Lett 100-101:277-285, 1998
40. D'HOOGE R, RAES A, LEBRUN P, et al: N-methyl-D-aspartate receptor activation by guanidinosuccinate but not by methylguanidine: Behavioural and electrophysiological evidence. Neuropharmacology 35:433-440, 1996
41. DE DEYN PP, MARESCAU B, CUYKENS JJ, et al: Guanidino compounds in serum and cerebrospinal fluid of non-dialysed patients with renal insufficiency. Clin Chim Acta 167:81-88, 1987
42. DE DEYN PP, MARESCAU B, D'HOOGE R, et al: Guanidino compound levels in brain regions of non-dialysed uremic patients. Neurochem Int 27:227-237, 1995
43. DE DEYN PP, MACDONALD RL: Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 28:627-633, 1990
44. D'HOOGE R, DE DEYN PP, VAN DE VIJVER G, et al: Uraemic guanidino compounds inhibit γ-aminobutyric acid-evoked whole-cell currents in mouse spinal cord neurons. Neurosci Lett 265:83-86, 1999
45. DE DEYN PP, D'HOOGE R, VAN BOGAERT PP, MARESCAU B: Endogenous guanidino compounds as uremic neurotoxins. Kidney Int 59 (Suppl 78):S77-S83, 2001
46. CAMPBELL RA: Polyamines and uremia, in Uremic Toxins, edited by RINGOIR S, VANHOLDER R, MASSRY SG, New York, Plenum Press, 1987, pp 47-54
47. SPRAGG BP, BENTLEY DP, COLES GA: Anaemia of chronic renal failure. Polyamines are not raised in uraemic serum. Nephron 38:65-66, 1984
48. CAMPBELL RA, GRETTIE DP, BARTOS F, et al: Uremic polyamine dysmetabolism. Proc Clin Dial Transplant Forum 8:194-198, 1978
49. SAITO A, TAKAGI T, CHUNG TG, OHTA K: Serum levels of polyamines in patients with chronic renal failure. Kidney Int 24(Suppl 16):S234-S237, 1983
50. SHAW GG, PATEMAN AJ: The regional distribution of the polyamines spermidine and spermine in brain. J Neurochem 20:1225-1230, 1973
51. SEILER N, BOLKENIUS FN: Polyamine reutilization and turnover in brain. Neurochem Res 10:529-544, 1985
52. ANDERSON DJ, CROSSLAND J, SHAW GG: The actions of spermidine and spermine on the central nervous system. Neuropharmacology 14:571-577, 1975
53. SCOTT RH, SUTTON KG, DOLPHIN AC: Interactions of polyamines with neuronal ion channels. Trends Neurosci 16:153-160, 1993
54. BOURDIOL F, FAGE D, SERRANO A, et al: Neurotoxic effects of the intrastratial injection of spermine and spermidine: Lack of involvement of NMDA receptors. Brain Res 596:183-188, 1992
55. CONWAY EL: Brain lesions and delayed water maze learning after intracerebroventricular spermine. Brain Res 800:10-20, 1998
56. KEW JNC, KEMP JA: An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 512:17-28, 1998
57. ROCK DM, MACDONALD RL: Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol 35:463-482, 1995
58. ARANEDA RC, ZUKIN RS, BENNETT MLV: Effects of polyamines on NMDA-induced currents in rat hippocampal neurons: A whole-cell and single-channel study. Neurosci Lett 152:107-112, 1993
59. SHAW GG: Some pharmacological properties of the polyamines spermine and spermidine - A re-appraisal. Arch Int Pharmacodyn 198:36-48, 1972
60. SINGH L, OLES R, WOODRUFF G: In vivo interaction of a polyamine with the NMDA receptor. Eur J Pharmacol 180:391-392, 1990
61. DOYLE KM, SHAW GG: Investigation of the involvement of the N-methyl-D-aspartate receptor macrocomplex in the development of spermine-induced CNS excitation in vivo. Br J Pharmacol 117:1803-1808, 1996
62. DOYLE KM, SHAW GG: Investigation of the actions and antagonist activity of some polyamine analogues in vivo. Br J Pharmacol 124:386-390, 1998
63. FRASER CL, SARNACKI P, ARIEFF AI: Abnormal sodium transport in synaptosomes from brain of uremic rats. J Clin Invest 75:2014-2023, 1985
64. GUISADO R, ARIEFF AI, MASSRY SG, et al: Changes in the electroen-cephalogram in acute uremia. Effects of parathyroid hormone and brain electrolytes. J Clin Invest 55:738-745, 1975
65. COOPER JD, LAZAROWITZ VC, ARIEFF AI: Neurodiagnostic abnormalities in patients with acute renal failure. J Clin Invest 61:1448-1455, 1978
66. FRASER CL, SARNACKI P, ARIEFF AI: Calcium transport abnormality in uremic rat brain synaptosomes. J Clin Invest 76:1789-1795, 1985
67. LINDNER A, VANHOLDER R, DE SMET R, et al: HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump. Kidney Int 51:1042-1052, 1997